Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
EHA 2022
It was great to speak with @jeff_sharman of @WVCancer recently to hear the interim results from a cohort of the MorningSun study, which evaluated fixed-duration SC mosunetuzumab in older/unfit patients with previously untreated #DLBCL.
Watch here: 👉
Fixed-duration SC mosunetuzumab in older patients with previously untreated DLBCL: MorningSun trial
Jeff Sharman, MD, Sarah Cannon Research Institute at Willamette Valley Cancer Institute & Research Center, Eugene, OR,...
ow.ly
Is there a way to predict and prevent therapy-related myeloid neoplasms in patients undergoing chemotherapy or radiation?💭
We spoke with @DrPinkalDesai of @WeillCornell at #ASH25 to gain valuable insight into this – watch the interview here:
👉 👈
Predicting and preventing therapy-related myeloid neoplasms
Pinkal Desai, MD, MPH, Weill Cornell Medicine, New York, NY, discusses the findings of an ongoing study on predict...
ow.ly
🚨 LAST CHANCE TO REGISTER for our Post ASH 2025 #Myeloma Highlights taking place TOMORROW 🔬
Join leading experts Dr Doris Hansen, @nishjo76 & Prof. Salomon Manier as they unpack the latest advances and discuss how these findings could influence clinical practice💡🎙️
🩸
In an interview from #ASH25, Heather Landau (@MSKCancerCenter) presents data from the first 20 pts treated in the NEXICART-2 trial, a Phase I/II dose escalation/expansion study of the BCMA-directed #CARTCell therapy NXC-201 in R/R AL #amyloidosis.
Watch now: 👉
🎥 In a recent interview, @mpdrc of @AtriumHealthWFB provides guidance on selecting between JAK inhibitors for the management of patients with #myelofibrosis.
Click here to watch:
👉 👈
#MPNsm #HemOnc
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, ...
ow.ly
EHA 2022
It was great to speak with @jeff_sharman of @WVCancer recently to hear the interim results from a cohort of the MorningSun study, which evaluated fixed-duration SC mosunetuzumab in older/unfit patients with previously untreated #DLBCL.
Watch here: 👉
Fixed-duration SC mosunetuzumab in older patients with previously untreated DLBCL: MorningSun trial
Jeff Sharman, MD, Sarah Cannon Research Institute at Willamette Valley Cancer Institute & Research Center, Eugene, OR,...
ow.ly
Is there a way to predict and prevent therapy-related myeloid neoplasms in patients undergoing chemotherapy or radiation?💭
We spoke with @DrPinkalDesai of @WeillCornell at #ASH25 to gain valuable insight into this – watch the interview here:
👉 👈
Predicting and preventing therapy-related myeloid neoplasms
Pinkal Desai, MD, MPH, Weill Cornell Medicine, New York, NY, discusses the findings of an ongoing study on predict...
ow.ly
🚨 LAST CHANCE TO REGISTER for our Post ASH 2025 #Myeloma Highlights taking place TOMORROW 🔬
Join leading experts Dr Doris Hansen, @nishjo76 & Prof. Salomon Manier as they unpack the latest advances and discuss how these findings could influence clinical practice💡🎙️
🩸
In an interview from #ASH25, Heather Landau (@MSKCancerCenter) presents data from the first 20 pts treated in the NEXICART-2 trial, a Phase I/II dose escalation/expansion study of the BCMA-directed #CARTCell therapy NXC-201 in R/R AL #amyloidosis.
Watch now: 👉
🎥 In a recent interview, @mpdrc of @AtriumHealthWFB provides guidance on selecting between JAK inhibitors for the management of patients with #myelofibrosis.
Click here to watch:
👉 👈
#MPNsm #HemOnc
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, ...
ow.ly
